envelop
virus
evolv
membran
glycoprotein
gp
mediat
entri
host
cell
protein
import
target
antivir
therapi
vaccin
sever
effort
understand
combat
infect
sever
acut
respiratori
syndrom
coronaviru
sarscov
therefor
focus
viral
gp
known
spike
short
period
time
import
aspect
sarscov
sprotein
function
unravel
identif
angiotensinconvert
enzym
receptor
sarscov
provid
insight
viral
tropism
pathogenesi
wherea
map
function
domain
sprotein
enabl
inhibitor
gener
vaccin
design
basi
sarscov
sprotein
shown
effect
anim
consequ
attract
candid
vaccin
trial
human
discuss
sarscov
facilit
viral
entri
target
cell
illustr
current
approach
use
inhibit
process
novemb
new
form
infecti
pneumonia
known
sever
acut
respiratori
syndrom
sar
emerg
guangdong
provinc
mainland
china
aid
delay
respons
public
health
offici
diseas
experienc
global
spread
patient
diagnos
sar
countri
major
case
report
asia
absenc
effect
treatment
diseas
combat
sole
use
quarantin
measur
travel
restrict
howev
strategi
prove
effect
sar
epidem
stop
june
death
toll
sar
accumul
infect
patient
diseas
result
enorm
econom
damag
attempt
contain
sar
parallel
multicent
collabor
effort
scientist
identifi
analyz
infecti
agent
behind
diseas
investig
culmin
identif
novel
coronaviru
cov
sar
patient
follow
demonstr
viru
caus
diseas
sequenc
new
viru
becam
publicli
avail
shortli
discoveri
sarscov
groundwork
laid
analyz
combat
sar
molecular
level
viru
reemerg
sinc
juli
except
sever
case
laboratoryacquir
infect
one
natur
outbreak
result
four
infect
peopl
suggest
sar
probabl
develop
season
diseas
howev
sarscovrel
virus
detect
game
anim
commonli
sold
chines
market
probabl
viru
replic
anim
reservoir
therefor
sarscov
could
reintroduc
human
popul
time
prepar
scenario
develop
vaccin
therapeut
import
task
infect
host
cell
sarscov
initi
interact
viral
spike
protein
receptor
cell
surfac
essenti
step
viral
replic
crucial
role
cov
spread
sprotein
major
focu
sar
research
review
describ
interact
cellular
factor
drive
viral
entri
process
inhibit
sprotein
drive
entri
target
cell
cov
subdivid
three
phylogenet
group
human
cov
found
group
ii
depend
method
sequenc
analysi
use
sarscov
either
constitut
new
phylogenet
group
subgroup
group
ii
cov
organ
positivestrand
rna
genom
sarscov
kb
size
resembl
coronavirus
harbor
openread
frame
orf
encod
larg
polyprotein
requir
genom
replic
four
structur
protein
eight
addit
polypeptid
unclear
function
figur
replic
sarscov
briefli
describ
box
e
protein
incorpor
viral
envelop
sprotein
dimer
trimer
protrud
viral
membran
provid
cov
characterist
coronaresembl
shape
infect
target
cell
cov
driven
sprotein
facilit
attach
target
cell
promot
fusion
viral
cellular
membran
therebi
allow
insert
viral
genom
cellular
cytoplasm
cov
sprotein
organ
outer
subunit
known
harbor
receptorbind
domain
transmembran
subunit
known
contain
function
element
involv
membran
fusion
figur
notabl
glycoprotein
gp
highli
diverg
virus
includ
human
immunodefici
viru
hiv
exhibit
compar
architectur
figur
gp
refer
class
fusion
protein
use
similar
mechan
promot
membran
fusion
import
implic
therapeut
intervent
despit
similar
domain
organ
sarscov
sprotein
exhibit
signific
sequenc
ident
cov
sprotein
highest
sequenc
conserv
found
heptad
repeat
hr
locat
within
region
underlin
import
function
tabl
cov
sprotein
contain
ntermin
signal
peptid
facilit
transport
endoplasmat
reticulum
protein
extens
glycosyl
notabl
sarscov
harbor
consensu
site
nlink
glycosyl
bind
viral
gp
cellular
factor
receptor
enabl
entri
enhanc
viral
infect
therefor
variou
pathogen
includ
hiv
thought
interact
factor
dendrit
cell
dc
promot
spread
within
infect
individu
bind
hiv
dc
facilit
infect
nearbi
suscept
cell
mechan
complet
understood
lectin
dcsign
dendrit
cellspecif
icamgrab
nonintegrin
relat
molecul
might
instrument
process
dcsign
express
cell
line
bind
gp
hiv
catalyz
infect
adjac
receptorposit
cell
dcsign
also
interact
sarscov
sprotein
augment
infect
retrovir
particl
bear
sprotein
envelop
observ
reflect
effici
dcmediat
also
shown
gener
viral
glycoprotein
subdivid
ntermin
receptorbind
subunit
follow
subunit
contain
structur
element
requir
membran
fusion
fusogen
peptid
two
amino
acid
stretch
helic
symmetri
proteolyt
cleavag
subunit
hostcel
proteas
indic
triangular
arrow
function
region
within
sprotein
predict
use
sequenc
similar
closest
relat
coronaviru
member
abbrevi
aibv
avian
infecti
bronchiti
viru
hcov
human
cov
hr
heptad
repeat
mhv
murin
hepat
viru
sar
sever
acut
respiratori
syndrom
spike
protein
coronaviru
cov
particl
bind
cellular
receptor
promot
fusion
viral
cellular
membran
sarscov
transmiss
target
cell
howev
factor
dcsign
clearli
involv
viral
transfer
notabl
dc
permiss
viru
infect
indic
product
infect
requir
transmiss
howev
interact
sarscov
dc
could
contribut
sar
pathogenesi
attach
sarscov
dermal
dc
might
facilit
viral
spread
skin
wherea
dcsignposit
alveolar
macrophag
could
promot
sarscov
replic
lung
moreov
intern
sarscov
dc
might
provid
viru
mean
immun
escap
although
dc
enhanc
viral
infect
use
attach
factor
dcsign
engag
cellular
receptor
requir
infecti
entri
host
cell
first
essenti
step
cov
sdriven
infect
therefor
interact
sprotein
cellular
receptor
consequ
sprotein
ectodomain
sole
determin
cov
celltrop
receptorbind
domain
locat
subunit
exhibit
littl
conserv
cov
reflect
interact
differ
cellular
receptor
figur
tabl
thu
residu
sprotein
interact
metalloproteas
wherea
residu
murin
hepat
viru
mhv
sprotein
bind
carcinoembryon
antigenrel
cell
adhes
molecul
speciesspecif
differ
primari
sequenc
cognat
receptor
determin
host
rang
cov
highlight
specif
sprotein
interact
cellular
receptor
multipl
implic
cell
tropism
host
rang
inhibitor
develop
effort
sever
laboratori
focus
identif
cellular
receptor
sarscov
novemb
li
et
al
report
metallopeptidas
angiotensinconvert
enzym
receptor
sarscov
use
solubl
ig
fusion
protein
immunoprecipit
experi
lysat
vero
cell
cell
type
use
isol
sarscov
subsequ
proteom
analysi
reveal
highaffin
bind
partner
inhibit
sarscov
infect
suscept
cell
use
antibodi
conjunct
observ
express
otherwis
poorli
suscept
cell
line
strongli
augment
viral
replic
indic
protein
facilit
sarscov
infect
wang
et
al
also
identifi
sarscov
receptor
use
differ
approach
bind
studi
use
solubl
fragment
sarscov
sprotein
reveal
residu
minim
receptorbind
domain
initi
search
sprotein
residu
import
bind
point
latter
crucial
associ
howev
exact
region
contact
sprotein
remain
undetermin
recent
structur
ectodomain
resolv
reveal
two
ridg
flank
catalyt
site
molecular
model
suggest
ridg
might
interact
sprotein
interestingli
bind
inhibitor
probabl
also
substrat
induc
structur
chang
within
ridg
might
interfer
bind
sprotein
detail
analysi
requir
identifi
residu
within
sprotein
critic
interact
therefor
repres
attract
target
inhibitor
studi
might
also
import
implic
develop
small
anim
model
thu
african
green
monkey
enabl
effici
entri
sarscov
infect
macaqu
speci
reproduc
aspect
sar
human
viral
replic
mice
less
robust
induc
diseas
therefor
import
determin
potenti
reduc
interact
sarscov
sprotein
murin
limit
viral
spread
anim
gener
transgen
anim
warrant
carboxypeptidas
cleav
polypeptid
renalangiotensin
system
essenti
cardiac
function
express
variou
tissu
organ
importantli
major
target
cell
sarscov
pneumocyt
express
express
cell
line
correl
permiss
sarscov
sdriven
infect
indic
play
central
role
sarscov
replic
notabl
evid
requir
coreceptor
exist
altern
receptor
sarscov
entri
certain
tissu
report
date
howev
infect
organ
lung
might
contribut
sar
pathogenesi
exampl
small
intestin
enterocyt
express
permiss
sarscov
moreov
effici
infect
renal
epitheli
cell
differ
speci
isol
viru
kidney
tissu
sar
patient
suggest
sarscov
infect
kidney
cell
might
contribut
acut
renal
failur
observ
sar
patient
infect
intestin
enterocyt
kidney
cell
could
facilit
viral
transmiss
via
fece
viral
rna
detect
stool
sampl
sar
patient
howev
unclear
transmiss
via
fece
promot
viral
spread
outbreak
hepatocyt
sar
patient
also
found
infect
hepatoma
cell
line
highli
permiss
replic
sarscov
infect
hepatocyt
might
therefor
partial
account
alter
level
liverspecif
enzym
commonli
observ
sar
patient
liver
tissu
found
larg
neg
protein
express
interest
examin
viral
entri
facilit
low
level
differ
factor
receptor
engag
activ
fusion
machineri
viral
gp
two
way
figur
first
bind
receptor
directli
activ
fusion
process
case
hiv
murin
leukemia
viru
mlv
gp
altern
receptor
engag
trigger
intern
viral
particl
endosom
proton
activ
gpdriven
membran
fusion
influenza
hemagglutinin
vesicular
stomat
viru
gprotein
vsvg
activ
low
ph
inhibitor
vacuolar
acidif
block
infect
sbear
pseudotyp
indic
low
ph
trigger
fusion
activ
sarscov
sprotein
figur
howev
sarscov
sdriven
celltocel
fusion
occur
absenc
low
ph
least
condit
gp
receptor
overexpress
therefor
sprotein
sarscov
might
abl
mediat
membran
fusion
phdepend
independ
fashion
sever
paramet
might
control
stimulu
requir
one
paramet
could
associ
subunit
sarscov
sprotein
mani
class
fusion
protein
cleav
outer
transmembran
subunit
cellular
proteas
cleavag
essenti
function
contrast
sprotein
group
cov
cleav
cleavag
sprotein
mhv
group
ii
cov
appear
celltyp
depend
requir
function
obviou
consensu
site
cellular
proteas
detect
sarscov
effici
cleavag
protein
report
although
cell
type
need
examin
notabl
proteas
altern
bind
receptor
follow
uptak
virion
endosom
compart
right
proton
influx
endosom
trigger
membran
fusion
activ
gp
inhibitor
acidif
ammonium
chlorid
nh
cl
bafilomycin
baf
use
dissect
pathway
specif
block
phdepend
membran
fusion
entri
sarscov
sbear
particl
endosom
pathway
appear
import
howev
acid
environ
shown
dispens
fusion
cell
express
sprotein
adjoin
cell
express
sarscov
receptor
angiotensinconvert
enzym
review
trend
microbiolog
octob
treatment
sexpress
cell
increas
celltocel
fusion
indic
cleavag
might
enabl
phindepend
receptordepend
trigger
fusion
activ
trigger
sarscov
sdriven
membran
fusion
possibl
cleavag
cellular
proteas
await
investig
two
function
element
locat
transmembran
subunit
cov
sprotein
pivot
membran
fusion
put
fusion
peptid
two
hr
figur
function
element
elucid
context
prototyp
class
fusion
protein
hiv
cleavag
produc
fusion
activ
form
transmembran
subunit
orient
perpendicular
viral
membran
contain
fusion
peptid
stretch
hydrophob
amino
acid
nterminu
two
hr
locat
fusion
peptid
transmembran
domain
fusion
process
fusion
peptid
insert
target
cell
membran
fold
back
onto
sixhelix
bundl
structur
trimer
dimer
form
conform
hr
orient
antiparallel
fashion
therebi
bring
fusion
peptid
insert
target
cell
membran
transmembran
domain
insert
viral
membran
close
contact
ultim
promot
membran
fusion
bosch
et
al
demonstr
fusion
driven
sprotein
mhv
follow
similar
principl
howev
major
differ
note
cleavag
mani
cov
sprotein
includ
sarscov
dispens
function
therefor
protein
must
harbor
intern
fusion
peptid
similar
gprotein
vsv
computerbas
analysi
predict
potenti
fusion
peptid
nterminu
sarscov
light
observ
model
membran
fusion
illustr
previous
must
revis
sarscov
sprotein
thu
upon
exposur
low
ph
probabl
intern
fusion
peptid
coval
associ
subunit
insert
target
cell
membran
membran
fusion
driven
format
sixhelix
bundl
figur
case
influenza
ha
low
ph
environ
trigger
irrevers
conform
chang
associ
membran
fusion
wherea
exposur
vsvg
low
ph
induc
revers
transit
fusion
activ
state
natur
phinduc
conform
chang
sarscov
sprotein
remain
determin
model
propos
accur
describ
sarscov
sdriven
membran
fusion
one
would
expect
peptid
mimick
assembl
sixhelix
bundl
peptid
would
inhibit
sarscov
smediat
membran
fusion
latter
specul
base
evid
obtain
sever
viral
class
fusion
protein
includ
mhv
sprotein
hrderiv
peptid
shown
inhibit
fusion
prevent
format
sixhelix
bundl
peptid
potent
inhibit
membran
fusion
driven
subunit
contain
put
fusion
peptid
two
heptad
repeat
hr
upon
insert
fusion
peptid
host
cell
membran
fold
back
onto
form
highli
stabl
sixhelix
bundl
format
six
helix
bundl
bring
viral
host
cell
membran
close
proxim
ultim
promot
membran
fusion
upper
panel
hiv
membran
fusion
present
lownanomolar
rang
approv
use
patient
constitut
first
member
entri
inhibitor
new
class
therapeut
sever
recent
studi
inde
report
sarscov
smediat
fusion
inhibit
peptid
gener
reflect
situat
observ
hiv
mix
sarscov
peptid
result
format
sixhelix
bundl
peptid
orient
antiparallel
fashion
residu
found
crucial
interact
one
except
micromolar
concentr
peptid
requir
effici
inhibit
viral
infect
indic
although
peptid
effect
optim
requir
achiev
effici
inhibit
sarscov
infect
individu
therapeut
approach
target
sarscov
entri
limit
imped
membran
fusion
reaction
polypeptid
deriv
portion
sarscov
shown
block
infect
possibl
occupi
sbind
site
moreov
purifi
ectodomain
specif
inhibit
sdriven
infect
need
assess
smaller
portion
also
exhibit
block
activ
pend
identif
sbind
site
greatli
facilit
studi
cov
sprotein
major
target
humor
cellular
immun
respons
constitut
prime
candid
vaccin
develop
vaccin
mice
sarscov
sencod
dna
trigger
humor
cellular
immun
respons
induc
protect
infect
deplet
cell
ig
transfer
experi
reveal
protect
due
neutral
antibodi
protect
achiev
sole
administr
sspecif
neutral
monoclon
antibodi
product
neutral
antibodi
also
observ
upon
immun
macaqu
adenoviru
mice
vaccinia
viru
encod
sprotein
latter
case
protect
vaccin
anim
sarscov
demonstr
data
conjunct
neutral
sdriven
infect
use
sera
obtain
convalesc
sar
patient
also
use
monoclon
antibodi
direct
subunit
indic
sbase
vaccin
promis
futur
human
trial
howev
trigger
inflamm
svaccin
control
anim
also
report
enhanc
effect
sspecif
antibodi
felin
infecti
periton
viru
replic
well
establish
therefor
sbase
vaccin
need
care
character
sever
anim
model
administ
human
conclud
remark
major
receptor
sarscov
interact
sprotein
target
therapeut
vaccin
sarscov
sprotein
class
fusion
protein
inhibit
strategi
known
effect
relat
viral
gp
fusion
inhibitor
alreadi
avail
complement
compound
target
differ
step
sarscov
entri
vaccin
design
basi
sprotein
promis
requir
thorough
evalu
variou
anim
model
administr
human
futur
studi
reveal
detail
insight
structur
organ
membran
fusion
activ
sprotein
turn
facilit
gener
potent
inhibitor
vaccin
candid
